Amarin faces another setback on expanded use of its lead drug

(Reuters) - Amarin Corp Plc said the Food and Drug Administration did not accept its appeal for the review of a regulatory decision to revoke an agreement related to the trial of its lead drug that lowers a type of blood fat. Amarin said on October 29 that the FDA rescinded the agreement which guaranteed that the design of a late-stage trial of Amarin's triglyceride-lowering drug Vascepa was adequate to support a marketing application. The trial, Anchor, was testing Vascepa in patients who also take a cholesterol-lowering statin such as Pfizer Inc's Lipitor and are at a high risk of coronary heart disease. Amarin is awaiting FDA decision on the use of the drug for the broader population.



via Health News Headlines - Yahoo! News http://news.yahoo.com/amarin-faces-another-setback-expanded-lead-drug-124242586--finance.html